• Age ≥ 18 years,

• ECOG, Performance status ≤ 1,

• Minimum 3 measurable lesions, with at least one lesion which cannot be irradiated for testing the abscopal effect and at least 2 irradiable lesions.

• Life expectancy \> 6 months,

• At least one non irradiated tumor site that can be biopsied for research purpose,

• Participant must have following advanced disease and must not be a candidate for other approved therapeutic regimen known to provide significant clinical benefit based on investigator judgement:

⁃ Cohort 1 : patient with metastatic non small lung cancer / tumor without oncogenic addiction (EGFR/ALK/ROS/BRAF) which progress after platin based chemotherapy and immunotherapy given as sequential or concomitant therapy.

⁃ Cohort 2 : Bladder cancer / Patient with progression following platin based therapy or without maintenance with anti PD1/PD-L1. Patient have to recieve Enfortumab Vedotin before inclusion if the treatment is available. Unless indication by the investigator Cohort 3 : Renal cell carcinoma / Second-line therapy after an anti-angiogenic plus immunotherapy or immunotherapy.

⁃ Cohort 4 : Head and neck carcinoma / First line locoregional or metastatic recurrence

• Participants who received prior anti-PD-1/L1 therapy must fulfill the following requirements Have achieved a complete response, partial response or stable disease and subsequently had disease progression while still on anti-PD-1/L1 therapy Have received at least two doses of an approved anti-PD-1/L1 therapy (by any regulatory authority)

• Adequate hematological, renal, metabolic and hepatic functions:

⁃ Hemoglobin ≥ 9 g/dl (participants may have received prior red blood cell \[RBC\] transfusion, if clinically indicated); absolute neutrophil count (ANC) ≥ 1.5 G/l, platelet count ≥ 100 G/l, white blood cell count ≥ 2.5 G/l (or within local laboratory normal limits) and lymphocyte count ≥ 0.75 G/l Alkaline phosphatase (AP), alanine aminotransferase (ALT) and aspartate aminotransferase (ASP) ≤ 2.5 x upper limit of normality (ULN) (≤ 5 x ULN in case of extensive skeletal involvement for AP exclusively and ≤ 5 x ULN in case of liver metastasis for AST and ALT).

⁃ Total bilirubin ≤ 1.5 x ULN, (3 x ULN for gilbert disease) Albumin ≥ 25 g/l. Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance (CrCl) ≥ 30 ml/min (according to Cockcroft and Gault formula).

⁃ INR ≤ 1.5 x ULN aPTT ≤ 1.5 X ULN Serum calcium within normal laboratory ranges,

• No prior or concurrent malignant disease if more recent than 3 years

• At least three weeks since last chemotherapy, immunotherapy or any other pharmacological treatment and/or radiotherapy

⁃ Criteria to confirm inclusion:

• At least 2 mesurable lesions should be able to receveid 3 X 8 Gy by SBRT according to the dose constraints to organs at risk (OAR) imposed by the protocol

• In case of lesion previously treated by radiotherapy, the constraints on the organs at risk must be respected after having summed up the treatment plans.

• Confirmation of 3 measureable lesions, with at least one lesion which cannot be irradiated for testing the abscopal effect and at least 2 irradiable lesions. Those lesions must be uni-dimensionally ≥ 10 mm considered as measurable according to RECIST v1.1